Skip to content
10-K

Annual Report

NewAmsterdam Pharma Company N.V. NAMS NAMSW

0001193125-26-056029

← back to feed
Filed
Feb 18, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 5, 2026 114.98M sh
Shares Diluted FY 2025 · Dec 31, 2025 118.42M sh
Shares Diluted FY 2025 · Dec 31, 2024 94.36M sh
Shares Diluted FY 2025 · Dec 31, 2023 82.16M sh
Capex FY 2025 · Dec 31, 2025 $246K
Capex FY 2025 · Dec 31, 2024 $672K
Capex FY 2025 · Dec 31, 2023 $24K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$147.78M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$158.56M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$141.22M
Cash And Equivalents FY 2025 · Dec 31, 2025 $490M
Cash And Equivalents FY 2025 · Dec 31, 2024 $771.74M
Cash And Equivalents FY 2025 · Dec 31, 2023 $340.45M
Stockholders Equity FY 2025 · Dec 31, 2025 $683.43M
Stockholders Equity FY 2025 · Dec 31, 2024 $757.5M
Stockholders Equity FY 2025 · Dec 31, 2023 $288.39M
Stockholders Equity FY 2025 · Dec 31, 2022 $430.07M
Current Liabilities FY 2025 · Dec 31, 2025 $85.79M
Current Liabilities FY 2025 · Dec 31, 2024 $106.92M
Total Liabilities FY 2025 · Dec 31, 2025 $85.85M
Total Liabilities FY 2025 · Dec 31, 2024 $107.12M
Current Assets FY 2025 · Dec 31, 2025 $675.7M
Current Assets FY 2025 · Dec 31, 2024 $863.41M
Total Assets FY 2025 · Dec 31, 2025 $769.28M
Total Assets FY 2025 · Dec 31, 2024 $864.62M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.72
Eps Diluted FY 2025 · Dec 31, 2024 −$2.56
Eps Diluted FY 2025 · Dec 31, 2023 −$2.15
Eps Basic FY 2025 · Dec 31, 2025 −$1.72
Eps Basic FY 2025 · Dec 31, 2024 −$2.56
Eps Basic FY 2025 · Dec 31, 2023 −$2.15
Sga Expense FY 2025 · Dec 31, 2025 $106.35M
Sga Expense FY 2025 · Dec 31, 2024 $70.45M
Sga Expense FY 2025 · Dec 31, 2023 $37.63M
Rd Expense FY 2025 · Dec 31, 2025 $141.83M
Rd Expense FY 2025 · Dec 31, 2024 $151.41M
Rd Expense FY 2025 · Dec 31, 2023 $159.42M
Net Income FY 2025 · Dec 31, 2025 −$203.82M
Net Income FY 2025 · Dec 31, 2024 −$241.6M
Net Income FY 2025 · Dec 31, 2023 −$176.94M
Operating Income FY 2025 · Dec 31, 2025 −$225.68M
Operating Income FY 2025 · Dec 31, 2024 −$176.29M
Operating Income FY 2025 · Dec 31, 2023 −$182.97M
Revenue FY 2025 · Dec 31, 2025 $22.5M
Revenue FY 2025 · Dec 31, 2024 $45.56M
Revenue FY 2025 · Dec 31, 2023 $14.09M